Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
Company profile
Ticker
XERS
Exchange
Website
CEO
paul Edick
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Latest filings (excl ownership)
15-12B
Securities registration termination
15 Oct 21
EFFECT
Notice of effectiveness
7 Oct 21
25-NSE
Exchange delisting
5 Oct 21
POS AM
Prospectus update (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 21
8-K
Completion of Acquisition or Disposition of Assets
5 Oct 21
8-K
Entry into a Material Definitive Agreement
5 Oct 21
Latest ownership filings
SC 13G/A
Sessa Capital (Master), L.P.
14 Feb 22
4
BARBARA-JEAN ANNE BORMANN-KENNEDY
5 Oct 21
4
JEFFREY W SHERMAN
5 Oct 21
4
John P. Schmid
5 Oct 21
4
DAWN HALKUFF
5 Oct 21
4
Paul R Edick
5 Oct 21
4
Steven Pieper
5 Oct 21
4
STEVEN PRESTRELSKI
5 Oct 21
4
Beth Hecht
5 Oct 21
4
KENNETH ERLAND JOHNSON
5 Oct 21
Financial summary
Quarter (USD) | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 63.60 mm | 63.60 mm | 63.60 mm | 63.60 mm | 63.60 mm | 63.60 mm |
Cash burn (monthly) | 1.00 mm | 3.24 mm | 8.60 mm | 6.30 mm | 6.67 mm | 5.99 mm |
Cash used (since last report) | 33.89 mm | 109.57 mm | 290.80 mm | 213.18 mm | 225.79 mm | 202.52 mm |
Cash remaining | 29.71 mm | -45.98 mm | -227.21 mm | -149.58 mm | -162.19 mm | -138.92 mm |
Runway (months of cash) | 29.7 | -14.2 | -26.4 | -23.7 | -24.3 | -23.2 |
Institutional ownership, Q3 2023
45.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 112 |
Opened positions | 17 |
Closed positions | 10 |
Increased positions | 36 |
Reduced positions | 24 |
13F shares | Current |
---|---|
Total value | 100.48 bn |
Total shares | 64.10 mm |
Total puts | 51.40 k |
Total calls | 473.60 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 9.37 mm | $17.44 bn |
Vanguard | 7.03 mm | $13.07 bn |
Stonepine Capital Management | 5.92 mm | $11.00 bn |
Flynn James E | 5.88 mm | $17.24 mm |
Caxton | 5.64 mm | $10.49 bn |
MPM Oncology Impact Management | 3.99 mm | $7.42 bn |
Sessa Capital | 3.26 mm | $0.00 |
Geode Capital Management | 2.77 mm | $5.16 bn |
STT State Street | 2.57 mm | $4.78 bn |
Millennium Management | 2.27 mm | $4.23 bn |